Relationship Between Oxidized LDL,IgM,and IgG Autoantibodies to ox-LDL Levels With Recurrent Cardiovascular Events in Swedish Patients With Previous Myocardial Infarction
Restricted accessResearch articleFirst published online November, 2014
Relationship Between Oxidized LDL,IgM,and IgG Autoantibodies to ox-LDL Levels With Recurrent Cardiovascular Events in Swedish Patients With Previous Myocardial Infarction
We determined whether plasma levels of circulating oxidized low-density lipoprotein (LDL; E06), immunoglobulin (Ig) G, and IgM autoantibodies binding to malonyldialdehyde-modified LDL (MDA-LDL) may predict cardiovascular events (CVEs). Patients (n = 123) with a previous myocardial infarction (MI) were included. The primary end point was defined as any of the following: cardiovascular death from any cause, nonfatal reinfarction or stroke, percutaneous coronary intervention, coronary artery bypass grafting, and hospitalization due to angina pectoris. There were 43 CVEs during the follow-up period of 8.4 ± 3.5 years. There was no significant difference in the levels of E06 and MDA-LDL IgG between the CVE and the event-free group. However, MDA-LDL IgM levels were significantly lower in patients in the CVE group (9524 ± 6326 relative light unit [RLU]) compared with the event-free (10 975 ± 5398 RLU) group (P = .04). In conclusion, levels of MDA-LDL IgM were associated with an increased risk of CVE in patients with a previous MI.
MikhailidisDPElisafMRizzoM. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol. 2011;9(5):533–571.
2.
AustinMABreslowJLHennekensCHBuringJEWillettWCKraussRM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988;260(13):1917–1921.
3.
AnberVMillarJSMcconnelMShepherdJPackardCJ. Interaction of very low-density, intermediate-density and low-density lipoproteins with human arterial wall proteoglycans. Arterioscler Thromb Vasc Biol. 1997;17(11):2507–2514.
4.
KraussRM. Atherogenic lipoprotein phenotype and diet-gene interactions. J Nutr. 2001;131(2):340S–343S.
5.
NielsenLB. Transfer of low-density lipoprotein into the arterial wall and risk of atherosclerosis. Atherosclerosis. 1996;123(1-2):1–15.
6.
PalinskiWRosenfeldMEYlä-HerttualaS. Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA. 1989;86(4):1372–1376.
7.
TsimikasSGlassCSteinbergD. Lipoproteins, lipoprotein oxidation and atherogenesis. In: KRChien, editor. Molecular Basis of Cardiovascular Disease: A Companion to Braunwald’s Heart Disease. Philadelphia: W.B. Saunders Company; 2004:385–413.
8.
Ylä-HerttualaSPalinskiWButlerSWPicardSSteinbergDWitztumJL. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb. 1994;14(1):32–40.
9.
TsimikasSPalinskiWHalpernSEYeungDWCurtissLKWitztumJL. Radiolabeled MDA2, an oxidation-specific, monoclonal antibody, identifies native atherosclerotic lesions in vivo. J Nucl Cardiol. 1999;6(1 pt 1):41–53.
10.
NavabMAnanthramaiahGMReddyST. Thematic review series: the pathogenesis of atherosclerosis: the oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res. 2004;45(6):993–1007.
11.
MatsumotoTTakashimaHOhiraN. Plasma level of oxidized low-density lipoprotein is an independent determinant of coronary macrovasomotor and microvasomotor responses induced by bradykinin. J Am Coll Cardiol. 2004;44(2):451–457.
12.
TsimikasSBrilakisESMillerER. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med. 2005;353(1):46–57.
13.
HolvoetPHarrisTBTracyRP. Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly: findings from the health, aging, and body composition study. Arterioscler Thromb Vasc Biol. 2003;23(8):1444–1448.
14.
TanagaKBujoHInoueM. Increased circulating malondialdehyde-modified LDL levels in patients with coronary artery diseases and their association with peak sizes of LDL particles. Arterioscler Thromb Vasc Biol. 2002;22(4):662–666.
15.
HolvoetPKritchevskySBTracyRP. The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. Diabetes. 2004;53(4):1068–1073.
16.
SjogrenPBasuSRosellM. Measures of oxidized low-density lipoprotein and oxidative stress are not related and not elevated in otherwise healthy men with the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2005;25(12):2580–2586.
17.
CrisbyMKublickieneKHenarehLAgewallS. Circulating levels of autoantibodies to oxidized low-density lipoprotein and C-reactive protein levels correlate with endothelial function in resistance arteries in men with coronary heart disease. Heart Vessels. 2009;24(2):90–95.
18.
NishiKItabeHUnoM. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol. 2002;22(10):1649–1654.
19.
AlpertJSThygesenKAntmanEBassandJP. Myocardial infarction redefined—a consensus document of the joint European society of cardiology/American college of cardiology committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36(3):959–969.
20.
PalinskiWHorkkoSMillerE. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice: demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest. 1996;98(3):800–814.
21.
TsimikasSBergmarkCBeyerRW. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol. 2003;41(3):360–370.
22.
ErkkilaATNarvanenOLehtoSUusitupaMIYlä-HerttualaS. Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease. Arterioscler Thromb Vasc Biol. 2000;20(1):204–209.
23.
PalinskiWMillerERWitztumJL. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci USA. 1995;92(3):821–825.
24.
TsimikasSPalinskiWWitztumJL. Circulating autoantibodies to oxidized LDL correlate with arterial accumulation and depletion of oxidized LDL in LDL receptor deficient mice. Arterioscl Thromb Vasc Biol. 2001;21(1):95–100.
25.
RavandiABoekholdtSMMallatZ. Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study. J Lipid Res. 2011;52(10):1829–1836.
26.
HörkköSBirdDAMillerE. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid–protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest. 1999;103(1):117–128.
27.
TsimikasSWitztumJLMillerER. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation. 2004;110(11):1406–1412.
28.
TsimikasSWilleitPWilleitJ. Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events. J Am Coll Cardiol. 2012;60(21):2218–2229.
29.
ShimadaKMokunoHMatsunagaE. Circulating oxidized low-density lipoprotein is an independent predictor for cardiac event in patients with coronary artery disease. Atherosclerosis. 2004; 174(2):343–347.
30.
TsimikasSMiyanoharaAHartvigsenK. Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression. J Am Coll Cardiol. 2011;58(16):1715–1727.
31.
Faria-NetoJRChyuKYLiX. Passive immunization with monoclonal IgM antibodies against phosphorylcholine reduces accelerated vein graft atherosclerosis in apolipoprotein E-null mice. Atherosclerosis. 2006;189(1):83–90.
